利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16117 条记录 (耗时 0.041 秒)

    Inducible expression from transposon-based vectors and uses
    71.
    发明授权
    Inducible expression from transposon-based vectors and uses 有权

    公开(公告)号：US11261462B2

    公开(公告)日：2022-03-01

    申请号：US16286573

    申请日：2019-02-26

    申请人： Just-Evotec Biologics, Inc.

    发明人： Jeffrey T. McGrew ,  Pauline S. Smidt ,  E-Ching Ong

    IPC分类号： C12N15/00 ,  C12N15/86 ,  C07K16/00 ,  C12N15/90 ,  C12N5/00

    摘要： Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5′ PiggyBac ITR and a 3′ PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.

    Type VI-E and type VI-F CRISPR-Cas system and uses thereof
    74.
    发明授权
    Type VI-E and type VI-F CRISPR-Cas system and uses thereof 有权

    公开(公告)号：US11225659B2

    公开(公告)日：2022-01-18

    申请号：US16864982

    申请日：2020-05-01

    申请人： HuiGene Therapeutics Co., Ltd.

    发明人： Hui Yang ,  Chunlong Xu ,  Yingsi Zhou ,  Qingquan Xiao

    IPC分类号： C12N15/00 ,  C12N15/11 ,  C12N9/22 ,  C12N15/90

    摘要： The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13e or Cas13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRNA) or crRNA. The novel Cas effector proteins are among the smallest of the known Cas effector proteins, at about 800 amino acids in size, and are thus uniquely suitable for delivery using vectors of small capacity, such as an AAV vector.

    Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells
    76.
    发明授权
    Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells 有权

    公开(公告)号：US11186820B2

    公开(公告)日：2021-11-30

    申请号：US16109218

    申请日：2018-08-22

    申请人： Procella Therapeutics AB

    发明人： Kenneth R. Chien ,  Jonathan Clarke ,  Chuen Yan Leung

    IPC分类号： C12N5/073 ,  C12N5/077 ,  C07K16/28 ,  A01K67/027 ,  C12N15/00 ,  G01N33/50

    摘要： The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

    Tumor determination method
    80.
    发明授权
    Tumor determination method 有权

    公开(公告)号：US11142801B2

    公开(公告)日：2021-10-12

    申请号：US15766631

    申请日：2016-10-07

    申请人： JAPANESE FOUNDATION FOR CANCER RESEARCH ,  SEKISUI MEDICAL CO., LTD.

    发明人： Masami Arai ,  Sachio Nomura ,  Yuriko Nemoto ,  Takuya Yotani

    IPC分类号： C12P19/34 ,  C12Q1/6886 ,  G01N30/88 ,  G01N30/02 ,  C12Q1/68 ,  C12N15/09 ,  C12N15/00 ,  C12Q1/6806 ,  B01J20/281

    摘要： It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.